“We’re pleased to have presented on these important topics at the ISPOR International Meeting,” stated DCR Vice President of Clinical Research Mahesh Krishnan. “At DCR, our goal is to continuously contribute to the science, whether it be our budget impact and cost-effectiveness modeling, psychometric development, commercial reimbursement or policy analytics.”
Dr. Deborah Lubeck, one of the industry’s most respected health economics experts and DCR’s new director of health economics, was among the DCR experts attending the ISPOR International Meeting.
An author of more than 160 publications, Lubeck held previous positions at PAREXEL, ICON, Genentech, Amgen and Stanford University. She was co-principal investigator of a registry at the University of California, San Francisco, with more than 10,000 prostate cancer patients. She received her PhD in economics at the University of California, Berkeley.
“We strive to acquire the best talent within the industry,” commented Krishnan. “Dr. Lubeck is one of the leading health economics experts of our time, and we’re proud to have her leading our HEOR team.”
DaVita, DaVita Clinical Research and DCR are trademarks or registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.